Current Headlines

  1. Revvity To Acquire Human Cell Design To Advance Human-Relevant Cell Models For Metabolic Disease Drug Discovery 9/9/2026

    Revvity, Inc. today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases.

  2. Alebund Pharmaceuticals Announces FDA Clearance Of IND Application For AP308 For The Treatment Of IgA Nephropathy 9/8/2026

    Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease.

  3. HeartBeat.bio And Cubase Bio Partner To Advance 3D Spatial Transcriptomics For Cardiovascular Drug Discovery 9/8/2026

    HeartBeat.bio AG, a TechBio company developing a human cardiac organoid-based drug discovery platform, and Cubase Bio, a genomics company developing true 3D spatial transcriptomics technologies, today announced a strategic research collaboration to advance spatial profiling of human cardiac organoids for cardiovascular drug discovery.

  4. Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential For Biological Age Reversal, As Assessed By Six Proteomic Aging Clocks 9/7/2026

    Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

  5. Acepodia Announces FDA Clearance Of IND Application For ACE723, A Novel Dual-Payload Antibody-Drug Conjugate 9/4/2026

    Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ACE723, a GPC3-targeted dual-payload antibody-drug conjugate (ADC) developed using Acepodia's proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

  6. Lupin Receives U.S. FDA Approval For Modafinil Tablets, USP 9/4/2026

    Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg.

  7. Kali Therapeutics Receives U.S. FDA Clearance For KT501 Investigational New Drug Application 9/3/2026

    Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for KT501.

  8. Nuffield Department Of Medicine At The University Of Oxford And 2U Launch New Program In AI-Driven Drug Discovery 9/3/2026

    2U, a global leader in higher education, today announced a new partnership with the Nuffield Department of Medicine (NDM) at the University of Oxford to launch the Oxford AI in Drug Discovery and Medicine Programme, a six-week online executive education program that equips scientists, researchers, and R&D professionals to apply artificial intelligence across the drug discovery pipeline while navigating the ethical and regulatory standards essential to modern biomedical research.

  9. Tigermed And Veeda Lifesciences Forge Strategic Clinical Research For Global Drug Development 9/3/2026

    Tigermed and Veeda Lifesciences – two global contract research organizations (CROs) rooted in China and India, respectively – announced a strategic alliance to create a unified China-India clinical research corridor.

  10. BenchSci Announces Two-Year Enterprise Agreement With Argenx To Advance AI-Driven Preclinical Drug Discovery 9/2/2026

    BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization.